Company intelligence / Profile preview
TheraVectys
Paris, Francetheravectys.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Preclinical
01
Overview
TheraVectys has developed a proprietary lentiviral vector immunotherapy platform that induces strong and durable T cell and antibody responses. The company’s lead programs target cancer and major infectious diseases. At least one therapeutic vaccine for Adult T-cell Leukemia/Lymphoma has advanced through preclinical optimization toward Phase I/II trials. Additional oncology programs were planned for early-phase clinical studies as of the last available updates.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineGene therapy (Lentiviral vector-based)Cell therapy (T-cell therapies)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Institut Pasteur – exclusive global licensing agreement on lentiviral vectors for vaccine applications; joint laboratory established with Institut Pasteur in Paris.
Beyond the preview
Go deeper on TheraVectys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraVectys.